Work

Responding to declining artemether lumefantrine efficacy in African malaria programs

Year: 2026
Type: article
Abstract: Recent U.S. CDC guidance extended artemether–lumefantrine (AL) treatment for uncomplicated malaria from 3 to 5 days, raising questions about its relevance to African programs. This recommendation, developed for U.S. clinical practice, does not by itself justify changing African national guidelines. Although artemisinin partial resistance and reduced AL efficacy have been reported at selected African sites, these findings do not establish that standard AL is ineffective across the continent. African trials comparing 3- and 5-day regimens have reported greater lumefantrine exposure with extended treatment, but increased exposure alone does not demonstrate better cure rates, reduced recrudescence or feasibility in routine care. This perspective argues for geographically targeted evaluation rather than blanket adoption. Such studies should integrate therapeutic efficacy outcomes with molecular resistance surveillance, pharmacokinetic data, medicine-quality verification, and assessments of adherence and implementation. Comparative studies should establish whether extended AL offers meaningful clinical advantages over standard AL or alternative effective ACTs before treatment-policy changes are considered.
Institution: Bowen University
Language: English
Field: Medicine
Open Access status: diamond
OpenAlex ID: W7236089384
FWCI:
Cites: 10
Cited by:
Related to: 10